BillionToOne, Inc. (BLLN) - Stock Analysis
Last updated: Jan 19, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profitability recovery ⢠Strong liquidity ⢠Negative equity BLLN achieved a clear operational turnaround in 2025 Q3âpositive EBITDA ($8.6M), net income ($5.7M) and free cash flow (+$7.9M) with ample short-term liquidity, but negative book equity and a high market cap versus recent revenue pose solvency and valuation risks.
Price Behavior
Key Price Behavior Insights: ⢠Downward momentum ⢠Failed rallies ⢠Support testing Support Level: $85.00 Resistance Level: $95â$100 Over the last month BLLN has trended sharply lower from around $130 to below $90, failing to hold rallies under $95â$100 and risking a decisive break of critical support near $85.
Sentiment & News
Key News Insights: ⢠2026 guidance ⢠Epic integration ⢠Japan trial BillionToOne is expanding commercial and clinical reachâannouncing 2026 guidance, an Epic EHR integration and Japan clinical trial selectionâwhile navigating market skepticism after a 52-week low.
AI Summary
BLLN has meaningfully pivoted from a cashâburn R&D story to a nascent commercial diagnostics company with multiâquarter liquidity and recent positive FCF, but the critical risk is that sustained profitability depends on either keeping R&D/SG&A cuts in place (threatening longâterm growth) or reâinvesting (which would compress margins), so investors should monitor quarterâoverâquarter revenue acceleration, repeatable FCF, Epic integration volume lift, and any signs of renewed spending or dilution.
Description
BillionToOne, Inc. is a precision diagnostics company that quantifies DNA at single-molecule resolution to support molecular diagnostic applications. Its platform underlies a non-invasive prenatal screen that evaluates fetal chromosomal and genetic risks from maternal blood and a suite of liquid biopsy tests for tumor mutation profiling and methylation-based monitoring of cancer burden. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | BLLN | BillionToOne, Inc. | BillionToOne (BLLN) is a hot IPO momentum candidate, with an 11% post-IPO rally, strong cash position, improving earnings metrics, and robust technical breakout above moving averages and upper Bollinger Band, although near-term overbought conditions suggest cautious positioning. | Closed | -11.5% |